

## Review

# Advancements in the Worldwide Detection of Severe Fever with Thrombocytopenia Syndrome Virus Infection from 2009 to 2023

Lin Ai<sup>1,✉</sup>; Wei Wang<sup>2,✉</sup>; Zheng Teng<sup>1,2,#</sup>

## ABSTRACT

Severe fever with thrombocytopenia syndrome (SFTS) is a growing concern as an emerging tick-borne infectious disease originating from the SFTS virus (SFTSV), a recent addition to the *Phlebovirus* genus under the family of bunyaviruses. SFTS is typically identified by symptoms such as fever, thrombocytopenia, leukopenia, and gastrointestinal problems, accompanied by a potentially high case fatality rate. Thus, early and accurate diagnosis is essential for effective treatment and disease management. This review delves into the existing methodologies for SFTS detection, including pathogenic, molecular, and immunological technologies.

## SEVERE FEVER WITH THROMBOCYTOPENIA SYNDROME

The severe fever with thrombocytopenia syndrome virus (SFTSV) is an emergent tick-borne virus causing severe fever and thrombocytopenia, accompanied by high mortality rates (1–2). Identified initially in 2009 within the Hubei Province, China, this virus fits into the *Bandavirus* genus of the *Phenuiviridae* family (3). It was later detected in Taiwan, China (4), Japan (5), the Republic of Korea (6), and Vietnam (7). Transmission of the SFTS disease is primarily via the arthropod vector, notably through tick bites (8). Transmission through animals such as cats (9), dogs (10), and cheetahs (11) is also reported. Cases of human-to-human transmission of SFTSV have been noted, involving contact with blood and bodily fluids, even in hospital settings (12–13). The potential for SFTSV transmission from pets to humans presents a risk to pet owners and veterinary professionals alike (9,14).

The clinical manifestation of SFTS typically presents with fever, thrombocytopenia, and leukocytopenia. Patients may also experience fatigue, chills, headaches, lymphadenopathy, and gastrointestinal symptoms, among other systemic manifestations like muscular

symptoms and coagulopathy (15). The case fatality rate of SFTS patients varies across China, the Republic of Korea, and Japan, ranging from approximately 6% to over 40% (2,16–17). The case fatality rate can escalate to 75% in cases complicated by hemophagocytic syndrome (18). The world is yet without an effective clinical treatment for this condition, and work on the development of an inactivated vaccine against SFTS is still in progress. Consequently, the World Health Organization has designated SFTSV as a priority pathogen that requires urgent attention (19).

A variety of detection methods for SFTSV have been developed, encompassing pathogenic, molecular, and immunological approaches. Pathogenic detection includes virus isolation via cell culture and electron microscopy techniques (3,20–21). Nucleic acid amplification techniques such as reverse transcription-polymerase chain reaction (RT-PCR) (22–23), loop-mediated isothermal amplification (LAMP) (24), and recombinase polymerase amplification (RPA) (25). Rapid diagnostic tests, such as lateral flow assays, provide prompt results and prove beneficial in resource-limited environments (3). Serological assays, including enzyme-linked immunosorbent assays (ELISAs) (26), indirect immunofluorescence assays (IFAs) (27), and immunochromatographic tests (ICTs) (28), remain the most extensively used methods for identifying SFTSV-specific antibodies in patient serum or plasma.

This review will summarize the current landscape of SFTSV detection methods. The critical importance of prompt and precise diagnosis of SFTSV infection in patient management and disease control underscores the necessity for the development of rapid, sensitive, and specific diagnostic methods.

## PATHOGENIC CHARACTERISTICS OF SFTSV

### Structural and Genetic Analysis of SFTSV

SFTSV, a negative-sense RNA virus from the

*Phenuiviridae* family, typically possesses a spherical or pleomorphic structure, with a diameter measuring between 80 and 120 nm. It is an enveloped virus, characterized by a lipid bilayer and surface glycoproteins that form spike-like features (20–21). The genome of SFTSV is segmented into three distinct negative-sense RNA strands, specifically designated as small (S), medium (M), and large (L) segments (20). The S segment, containing 1,744 nucleotides, codes for the nucleocapsid protein (N) (29–30). The M segment, made up of 3,378 nucleotides, is responsible for coding the glycoprotein precursor (GPC) (31). Lastly, the L segment, with 6,368 nucleotides, codes for the RNA-dependent RNA polymerase (RdRp) (32).

The SFTSV N protein is a highly conserved 116-amino acid protein that forms the nucleocapsid through its interaction with the viral RNA. The N protein is composed of two domains: the N-terminal domain that interacts with the RNA, and the C-terminal domain that is involved in oligomerization and protein-protein interactions (30).

The glycoprotein precursor of SFTSV undergoes post-translational cleavage, forming spikes on the surface of the virus. The Gn protein plays a critical role in attaching to the receptors of the host cell, while the Gc protein facilitates fusion with the membranes of the host cell (31).

The SFTSV RdRp is a large protein with multiple domains. The N-terminal region contains the RNA-binding and capping domains, while the C-terminal region contains the polymerase domain, responsible for catalyzing the RNA replication and transcription (32).

### Electron Microscopy (EM) for SFTSV

SFTSV presents as spherical or pleomorphic particles, with diameters ranging between 80 and 120 nm. The virus also features a lipid envelope with prominent surface spikes, approximately 12–20 nm in length, and houses a dense core protecting the vital genomic material, which was conducted by EM analysis (3). Then, the full-length structure and 3D model of SFTSV L protein by cryogenic EM were reported (28,33–34).

### Virus Isolation

This process of isolating SFTSV often includes the introduction of clinical samples or cell culture supernatants into susceptible cell lines. This is then followed by observing cytopathic effects (CPE) and the

verification of viral replication via molecular techniques (3). Numerous studies have reported success in isolating SFTSV from a range of sources, including patient samples, ticks, and animals that have been experimentally infected (3,35–39).

It's important to note that SFTSV can infect a variety of cells, including L929, Vero E6, Vero, and DH82 cells. However, CPEs were only identified in DH82 cells (3). Furthermore, Vero cells were employed to isolate SFTS at temperatures of 37 °C and 39 °C, suggesting that the SFTSV strain ZJ2013-06 from a patient demonstrated limited replication at 39 °C as per the research conducted by Feng et al. (35).

Ten infective SFTSVs were isolated successfully from various tick species in one 2021 study (38). Moreover, the viral sequences extracted from the ticks demonstrated remarkable homology to the sequences previously isolated from SFTS patients from the same region of sample collection.

Wei et al. (39) conducted a study on the ability of SFTSV to infect BEAS-2B cells. Utilizing cell culture techniques, they assessed the overall antibody production in the serum as well as the viral load in the tissue of mice infected with SFTSV via aerosol exposure.

Virus isolation has been utilized in the SFTSV transmission cycle. According to a study by Jiao et al., goats inoculated with SFTSV showed no disease signs and did not expel the virus through either respiratory or digestive routes. This finding suggests that without specific arthropod species as carriers, an efficacious viral transmission cycle cannot be established in natural conditions (36).

### NUCLEIC ACID DETECTION

Detection of SFTSV genome could be achieved by different nucleic acid detection techniques such as RT-PCR (13,40–43), real-time RT-PCR (23,28,41,44–48), LAMP (24,49–50), as well as RPA (25,51–52).

#### Conventional Nucleic Acid Detection

The S segment codes for the nucleocapsid protein — a crucial element for the processes of viral assembly and replication (29). A two-tube multiplex real-time RT-PCR assay, designed for the identification of four hemorrhagic fever viruses: SFTSV, Hantaan virus, Seoul virus, and the dengue virus. It targets the nucleocapsid protein in the SFTSV genome (47).

The ability to differentiate between SFTSV strains can be facilitated by the M segment. A one-step RT-PCR assay targeting this M segment was developed by Sun et al. (23), which exhibited high specificity and sensitivity and was capable of detecting as few as 10 copies of the viral RNA per reaction.

The L segment — responsible for encoding the RNA-dependent RNA polymerase — is frequently targeted in SFTSV RT-PCR assays due to its relatively preserved characteristics. This focus on the L segment affords significant specificity in the detection of SFTSV (32).

RT-PCR and real-time RT-PCR assays are widely used for the detection and quantification of SFTSV in clinical samples, such as blood, serum, and cerebrospinal fluid (43,53–55). They are also employed in epidemiological investigations, such as tick and animal infected surveillance, analysis of viral genetic diversity, as well as a crucial role in the evaluation of antiviral drugs and vaccines against SFTSV (9,36,56–61).

### Rapid Nucleic Acid Detection

The method of LAMP exhibits considerable potential for SFTSV detection given its efficiency, rapidity, and economic feasibility (62–63). The one-step, single-tube reverse transcription LAMP assay for rapid identification of RNA from SFTSV with a detection limit of  $10 \times 50\%$  tissue culture infective dose (TCID<sub>50</sub>) per mL, demonstrated high specificity and sensitivity. After combining with the fluorescent detection reagent (FDR) method, results could be determined by observing a color change within 30 min (64). Jang et al. developed a multiplex RT-LAMP to identify larger segments and GroES genes for SFTSV and *Orientia tsutsugamushi* (OT) (24). The sensitivity of the multiplex SFTSV/OT/Internal control (IC) RT-LAMP assay proved comparable to that of the commercial PowerChek™ SFTSV Real-time PCR (91.3% vs. 95.6%). Moreover, it displayed a higher sensitivity (91.6%) than the LiliF™ TSUTSU nested PCR (75%), with the multiplex SFTSV/OT RT-LAMP assay exhibited 100% specificity. The LAMP assay has been successfully implemented in clinical specimens from both humans (50,64–66) and cats (67), indicating promising applications.

RPA is a novel isothermal nucleic acid amplification technique that offers rapid, sensitive, and specific detection of SFTSV with constant temperature between 37 and 42 °C as well as eliminates the need for thermal cycling equipment (68–70). RPA assays

can be combined with various detection methods, such as fluorescence, lateral flow, or colorimetric detection, to facilitate rapid and straightforward readouts (71–72).

Zhou et al. implemented the RT-RPA assay to detect SFTSV in serum samples (25). The detection limit was illustrated to be 241 copies per reaction at a 95% probability, with a sensitivity and specificity rate of approximately 96.00% and 98.95% respectively. Thus, the rapid RT-RPA assay presents itself as a promising candidate for point-of-care detection methods of SFTSV.

The advent of molecular technology has facilitated the development of novel detection methods for SFTSV, utilizing CRISPR-Cas13a (73). Huang et al. (52) and Park et al. (74) applied CRISPR-Cas12a system combined with RT-RPA to detect SFTS. In Huang et al.'s report, three copies of the L gene from the SFTSV genome per reaction were enough to ensure stable detection within 40 min. In Park et al. research, it successfully diagnosed SFTSV infections with the reaction time of 50 min from blood plasma without cross-reactivity to other viruses.

## IMMUNOLOGICAL TEST

Serological assays, which detect SFTSV-specific antibodies in patients' or animals' serum or plasma, have been extensively utilized. These assays comprise ELISAs (26,35,75–78), IFAs (45,78), and ICTs (28).

### ELISAs for SFTSV Detection

Various SFTSV-specific antigens have been employed in ELISAs, encompassing SFTSV nucleocapsid protein (NP), glycoprotein (GP), and non-structural protein (NSs). Predominantly, NP-based ELISA is utilized and has demonstrated superior diagnostic precision for SFTSV serodiagnosis (26,79).

A sandwich ELISA predicated on recombinant N protein for the detection of total antibodies targeting this virus in humans and animals (36). SFTSV-specific IgM antibodies detectable in patient serum merely three days post-symptom onset, peaking approximately two weeks later, have also been revealed (78). Furthermore, SFTSV-specific IgG antibodies became detectable about six days post-symptom onset, persisting up to six months. In a report by Yu, recombinant SFTSV-N (rSFTSV-N) protein was produced using an *Escherichia coli* expression system and purified (80). Additionally, Yu established

rSFTSV-N protein-based IgG ELISA and IgM ELISA systems.

ELISA methods are currently being extensively utilized to monitor SFTSV infection in humans as well as animals. According to a report by Tran et al. (78), the seroprevalence of anti-SFTSV IgM or IgG was recorded at 3.64% (26 out of 714) with a high IgM antibodies positivity titer >80 (0.28%, 2 out of 714). Lee et al. (75) developed a competitive ELISA for diagnosing SFTSV in bovine sera using a monoclonal antibody where lab-immunized positive sera exhibited a 98.1% consistency with IFA results. A 2020 study by Duan et al. (81) introduced enzyme-antibody-modified gold nanoparticle probes for the ultrasensitive detection of the nucleocapsid protein in SFTSV, where the detection limit for NP was 0.9 pg/mL, demonstrating good specificity and reproducibility.

### Utilizing IFAs for the Detection of SFTSV

The IFA technique, which is recombinant antigen-based, utilizes recombinant viral proteins from a heterologous system as the source of the antigen. A case in point is the research conducted by Tran et al. whereby serum samples from 714 healthy Vietnamese residents were collected (78). To assess the SFTSV seroprevalence, the samples underwent IFA, ELISA, and the 50% focus reduction neutralization test (FRNT50) assay. The neutralizing antibodies against SFTSV recorded a range of 15.5 to 55.9 in terms of titer.

### Utilizing ICAs for SFTSV Detection

Upholding the principle of antigen-antibody interaction, immunochromatographic tests employ capillary action to transport the sample along the strip, where either antibodies or antigens are immobilized and labeled. (28).

Wang et al. (28) implemented the ICA method, which involves the use of gold nanoparticles coated with recombinant SFTSV to simultaneously detect both IgG and IgM antibodies to SFTSV. This method was developed and assessed using 245 positive serum samples from China CDC of SFTSV infection. The ensuing results revealed positive and negative coincidence rates of 98.4% and 100% for IgM, as well as 96.7% and 98.6% for IgG, respectively.

## DISCUSSION

In conclusion, a myriad of diagnostic methods have

emerged and have been implemented for recognizing SFTSV infection. This includes etiological, immunological, and molecular methodologies. While strides have been made in detecting SFTSV, substantial efforts remain regarding standardization and automation, along with the cultivation of multiplex assays for enhancing detection efficiency and accuracy. As a result, forthcoming research should prioritize resolving these challenges, whilst seeking novel diagnostic approaches that will aid us in battling this lethal disease.

For consistent and trustworthy results vital for patient care, it is essential that all labs adopt uniform methodologies and procedures for detecting SFTSV. Without such standardization, the validity and reliability of SFTSV detection can fluctuate across different labs, impeding effective identification and containment of virus outbreaks. Automating these techniques could enhance efficiency, minimize costs, and allow labs to tackle larger volumes of samples in less time. Moreover, automation mitigates the risk of human errors, thereby enhancing the accuracy and reliability of the results obtained. Implementing multiplex assays could notably enhance the effectiveness and accuracy of SFTSV detection. These assays allow for the simultaneous detection of multiple pathogens in a single sample. Consequently, labs could identify SFTSV as well as other tick-borne diseases with similar symptoms, such as *Anaplasma phagocytophilum* and *Borrelia burgdorferi*. Multiplex assays would be especially beneficial in environments where multiple tick-borne diseases are prevalent.

SFTSV represents a significant health threat that necessitates prompt and precise identification to facilitate appropriate treatment and manage potential outbreaks. It is recommended that standardization and automation be prioritized in conjunction with the development of multiplex assays to enhance the detection effectiveness and precision. The introduction of innovative diagnostic approaches, such as next-generation sequencing and biomarker recognition, could potentially yield more meticulous and sensitive detection methods for SFTSV. Undertaking these challenges is integral to the effective containment and prevention of this virus' spread.

**Conflicts of interest:** No conflicts of interest.

**Acknowledgements:** Jiayu Wang, Fanghao Fang, Huanru Wang, Jiajing Liu, Xue Zhao, and Run Li for their suggestion in the references collection.

**Funding:** Supported by the key research project of Three-Year Initiative Plan for Strengthening Public



# Health System Construction in Shanghai, Key Capabilities of Bio-security and Network Integration of Public Health Laboratory in Megacities (GW VI-3).

doi: 10.46234/ccdcw2023.132

# Corresponding author: Zheng Teng, tengzheng@scdc.sh.cn.

<sup>1</sup> Institute of Microbiology Laboratory, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China; <sup>2</sup> Institute of Microbiology Laboratory, Shanghai Institute of Preventive Medicine, Shanghai, China.

& Joint first authors.

Submitted: June 09, 2023; Accepted: August 01, 2023

## REFERENCES

- Li JC, Zhao J, Li H, Fang LQ, Liu W. Epidemiology, clinical characteristics, and treatment of severe fever with thrombocytopenia syndrome. *Infect Med* 2022;1(1):40 – 9. <http://dx.doi.org/10.1016/j.imj.2021.10.001>.
- Li J, Li S, Yang L, Cao PF, Lu JH. Severe fever with thrombocytopenia syndrome virus: a highly lethal bunyavirus. *Crit Rev Microbiol* 2021;47(1):112 – 25. <http://dx.doi.org/10.1080/1040841X.2020.1847037>.
- Yu XJ, Liang MF, Zhang SY, Liu Y, Li JD, Sun YL, et al. Fever with thrombocytopenia associated with a novel bunyavirus in China. *N Engl J Med* 2011;364(16):1523 – 32. <http://dx.doi.org/10.1056/NEJMoa1010095>.
- Lin TL, Ou SC, Maeda K, Shimoda H, Chan JPW, Tu WC, et al. The first discovery of severe fever with thrombocytopenia syndrome virus in Taiwan. *Emerg Microbes Infect* 2020;9(1):148 – 51. <http://dx.doi.org/10.1080/22221751.2019.1710436>.
- Takahashi T, Maeda K, Suzuki T, Ishido A, Shigeoka T, Tominaga T, et al. The first identification and retrospective study of severe fever with thrombocytopenia syndrome in Japan. *J Infect Dis* 2014;209(6):816 – 27. <http://dx.doi.org/10.1093/infdis/jit603>.
- Kim YR, Yun Y, Bae SG, Park D, Kim S, Lee JM, et al. Severe fever with thrombocytopenia syndrome virus infection, South Korea, 2010. *Emerg Infect Dis* 2018;24(11):2103 – 5. <http://dx.doi.org/10.3201/eid2411.170756>.
- Tran XC, Yun Y, Van An L, Kim SH, Thao NTP, Man PKC, et al. Endemic severe fever with thrombocytopenia syndrome, Vietnam. *Emerg Infect Dis* 2019;25(5):1029 – 31. <http://dx.doi.org/10.3201/eid2505.181463>.
- Liu Q, He B, Huang SY, Wei F, Zhu XQ. Severe fever with thrombocytopenia syndrome, an emerging tick-borne zoonosis. *Lancet Infect Dis* 2014;14(8):763 – 72. [http://dx.doi.org/10.1016/S1473-3099\(14\)70711-4](http://dx.doi.org/10.1016/S1473-3099(14)70711-4).
- Hwang J, Kang JG, Oh SS, Chae JB, Cho YK, Cho YS, et al. Molecular detection of severe fever with thrombocytopenia syndrome virus (SFTSV) in feral cats from Seoul, Korea. *Ticks Tick Borne Dis* 2017;8(1):9 – 12. <http://dx.doi.org/10.1016/j.ttbdis.2016.08.005>.
- Lee SH, Kim HJ, Byun JW, Lee MJ, Kim NH, Kim DH, et al. Molecular detection and phylogenetic analysis of severe fever with thrombocytopenia syndrome virus in shelter dogs and cats in the Republic of Korea. *Ticks Tick Borne Dis* 2017;8(4):626 – 30. <http://dx.doi.org/10.1016/j.ttbdis.2017.04.008>.
- Matsuno K, Nonoue N, Noda A, Kasajima N, Noguchi K, Takano A, et al. Fatal tickborne phlebovirus infection in captive cheetahs, Japan. *Emerg Infect Dis* 2018;24(9):1726 – 9. <http://dx.doi.org/10.3201/eid2409.171667>.
- Kim WY, Choi W, Park SW, Wang EB, Lee WJ, Jee Y, et al. Nosocomial transmission of severe fever with thrombocytopenia syndrome in Korea. *Clin Infect Dis* 2015;60(11):1681 – 3. <http://dx.doi.org/10.1093/cid/civ128>.
- Jung IY, Choi W, Kim J, Wang E, Park SW, Lee WJ, et al. Nosocomial person-to-person transmission of severe fever with thrombocytopenia syndrome. *Clin Microbiol Infect* 2019;25(5):633.e1 – 4. <http://dx.doi.org/10.1016/j.cmi.2019.01.006>.
- Huang XX, Li JD, Li AQ, Wang SW, Li DX. Epidemiological characteristics of severe fever with thrombocytopenia syndrome from 2010 to 2019 in Mainland China. *Int J Environ Res Public Health* 2021;18(6):3092. <http://dx.doi.org/10.3390/ijerph18063092>.
- Guo CT, Lu QB, Ding SJ, Hu CY, Hu JG, Wo Y, et al. Epidemiological and clinical characteristics of severe fever with thrombocytopenia syndrome (SFTS) in China: an integrated data analysis. *Epidemiol Infect* 2016;144(6):1345 – 54. <http://dx.doi.org/10.1017/S0950268815002678>.
- Choi SJ, Park SW, Bae IG, Kim SH, Ryu SY, Kim HA, et al. Severe fever with thrombocytopenia syndrome in South Korea, 2013–2015. *PLoS Negl Trop Dis* 2016;10(12):e0005264. <http://dx.doi.org/10.1371/journal.pntd.0005264>.
- Kato H, Yamagishi T, Shimada T, Matsui T, Shimojima M, Saijo M, et al. Epidemiological and clinical features of severe fever with thrombocytopenia syndrome in Japan, 2013–2014. *PLoS One* 2016;11(10):e0165207. <http://dx.doi.org/10.1371/journal.pone.0165207>.
- Jung IY, Ahn K, Kim J, Choi JY, Kim HY, Uh Y, et al. Higher fatality for severe fever with thrombocytopenia syndrome complicated by hemophagocytic lymphohistiocytosis. *Yonsei Med J* 2019;60(6):592 – 6. <http://dx.doi.org/10.3349/ymj.2019.60.6.592>.
- World Health Organization (WHO). 2018 Annual review of diseases prioritized under the Research and Development Blueprint. Geneva: WHO Research and Development Blueprint; 2018. [https://www.who.int/docs/default-source/blue-print/2018-annual-review-of-diseases-prioritized-under-the-research-and-development-blueprint.pdf?sfvrsn=4c22e36\\_2](https://www.who.int/docs/default-source/blue-print/2018-annual-review-of-diseases-prioritized-under-the-research-and-development-blueprint.pdf?sfvrsn=4c22e36_2).
- Liu JW, Zhao L, Luo LM, Liu MM, Sun Y, Su X, et al. Molecular evolution and spatial transmission of severe fever with thrombocytopenia syndrome virus based on complete genome sequences. *PLoS One* 2016;11(3):e0151677. <http://dx.doi.org/10.1371/journal.pone.0151677>.
- Yuan F, Zheng AH. Entry of severe fever with thrombocytopenia syndrome virus. *Virol Sin* 2017;32(1):44 – 50. <http://dx.doi.org/10.1007/s12250-016-3858-6>.
- Kim KH, Yi J, Kim G, Choi SJ, Jun KI, Kim NH, et al. Severe fever with thrombocytopenia syndrome, South Korea, 2012. *Emerg Infect Dis* 2013;19(11):1892 – 4. <http://dx.doi.org/10.3201/eid1911.130792>.
- Sun YL, Liang MF, Qu J, Jin C, Zhang QF, Li JD, et al. Early diagnosis of novel SFTS bunyavirus infection by quantitative real-time RT-PCR assay. *J Clin Virol* 2012;53(1):48 – 53. <http://dx.doi.org/10.1016/j.jcv.2011.09.031>.
- Jang WS, Lim DH, Choe YL, Nam J, Moon KC, Kim C, et al. Developing a multiplex loop-mediated isothermal amplification assay (LAMP) to determine severe fever with thrombocytopenia syndrome (SFTS) and scrub typhus. *PLoS One* 2022;17(2):e0262302. <http://dx.doi.org/10.1371/journal.pone.0262302>.
- Zhou JY, Wang QJ, Zhu LJ, Li SB, Li W, Fu YF, et al. Development and evaluation of a rapid detection assay for severe fever with thrombocytopenia syndrome virus based on reverse-transcription recombinase polymerase amplification. *Mol Cell Probes* 2020;52:101580. <http://dx.doi.org/10.1016/j.mcp.2020.101580>.
- Zhang M, Du Y, Yang L, Zhan L, Yang B, Huang X, et al. Development of monoclonal antibody based IgG and IgM ELISA for diagnosis of severe fever with thrombocytopenia syndrome virus infection. *Braz J Infect Dis* 2022;26(4):102386. <http://dx.doi.org/10.1016/j.bjid.2022.102386>.
- Liu W, Lu QB, Cui N, Li H, Wang LY, Liu K, et al. Case-fatality ratio and effectiveness of ribavirin therapy among hospitalized patients in China who had severe fever with thrombocytopenia syndrome. *Clin Infect Dis* 2013;57(9):1292 – 9. <http://dx.doi.org/10.1093/cid/cit530>.
- Wang XG, Zhang QF, Hao F, Gao XN, Wu W, Liang MY, et al. Development of a colloidal gold kit for the diagnosis of severe fever

- with thrombocytopenia syndrome virus infection. *Biomed Res Int* 2014;2014:530621. <http://dx.doi.org/10.1155/2014/530621>.
29. Jiao LY, Ouyang SY, Liang MF, Niu FF, Shaw N, Wu W, et al. Structure of severe fever with thrombocytopenia syndrome virus nucleocapsid protein in complex with suramin reveals therapeutic potential. *J Virol* 2013;87(12):6829 – 39. <http://dx.doi.org/10.1128/JVI.00672-13>.
  30. Lee SY, Lee H, Yun SH, Park EC, Seo G, Kim HY, et al. Proteomics-based diagnostic peptide discovery for severe fever with thrombocytopenia syndrome virus in patients. *Clin Proteomics* 2022;19(1):28. <http://dx.doi.org/10.1186/s12014-022-09366-w>.
  31. Guardado-Calvo P, Rey FA. The envelope proteins of the *Bunyavirales*. *Adv Virus Res* 2017;98:83 – 118. <http://dx.doi.org/10.1016/bs.aivir.2017.02.002>.
  32. Ren FL, Shen S, Ning YJ, Wang QY, Dai SY, Shi JM, et al. Non-structural proteins of severe fever with thrombocytopenia syndrome virus suppress RNA synthesis in a transcriptionally active cDNA-derived viral RNA synthesis system. *Front Microbiol* 2021;12:709517. <http://dx.doi.org/10.3389/fmicb.2021.709517>.
  33. Vogel D, Thorkelsson SR, Quemien ERJ, Meier K, Kouba T, Gogrefe N, et al. Structural and functional characterization of the severe fever with thrombocytopenia syndrome virus L protein. *Nucleic Acids Res* 2020;48(10):5749 – 65. <http://dx.doi.org/10.1093/nar/gkaa253>.
  34. Williams HM, Thorkelsson SR, Vogel D, Milewski M, Busch C, Cusack S, et al. Structural insights into viral genome replication by the severe fever with thrombocytopenia syndrome virus L protein. *Nucleic Acids Res* 2023;51(3):1424 – 42. <http://dx.doi.org/10.1093/nar/gkac1249>.
  35. Feng Y, Xu CP, Li CX, Lin JF, Wang ZF, Zhang YJ, et al. Replication capacity and adaptability of a severe fever with thrombocytopenia syndrome virus at different temperatures. *PLoS One* 2017;12(11):e0188462. <http://dx.doi.org/10.1371/journal.pone.0188462>.
  36. Jiao YJ, Qi X, Liu DP, Zeng XY, Han YW, Guo XL, et al. Experimental and natural infections of goats with severe fever with thrombocytopenia syndrome virus: evidence for ticks as viral vector. *PLoS Negl Trop Dis* 2015;9(10):e0004092. <http://dx.doi.org/10.1371/journal.pntd.0004092>.
  37. Jin C, Liang MF, Ning JY, Gu W, Jiang H, Wu W, et al. Pathogenesis of emerging severe fever with thrombocytopenia syndrome virus in C57/BL6 mouse model. *Proc Natl Acad Sci USA* 2012;109:10053 – 8. <http://dx.doi.org/10.1073/pnas.1120246109>.
  38. Sato Y, Mekata H, Sudaryatna PE, Kirino Y, Yamamoto S, Ando S, et al. Isolation of severe fever with thrombocytopenia syndrome virus from various tick species in area with human severe fever with thrombocytopenia syndrome cases. *Vector Borne Zoonotic Dis* 2021;21(5):378 – 84. <http://dx.doi.org/10.1089/vbz.2020.2720>.
  39. Wei XM, Li SH, Lu Y, Qiu L, Xu NN, Guo XH, et al. Severe fever with thrombocytopenia syndrome virus aerosol infection in C57/BL6 mice. *Virology* 2023;581:58 – 62. <http://dx.doi.org/10.1016/j.virol.2023.03.001>.
  40. Kim SY, Seo CW, Lee HI. Severe fever with thrombocytopenia syndrome virus from ticks: a molecular epidemiological study of a patient in the Republic of Korea. *Exp Appl Acarol* 2023;89(2):305 – 15. <http://dx.doi.org/10.1007/s10493-023-00783-6>.
  41. Li ZF, Qi X, Zhou MH, Bao CJ, Hu JL, Wu B, et al. A two-tube multiplex real-time RT-PCR assay for the detection of four hemorrhagic fever viruses: severe fever with thrombocytopenia syndrome virus, Hantaan virus, Seoul virus, and dengue virus. *Arch Virol* 2013;158(9):1857 – 63. <http://dx.doi.org/10.1007/s00705-013-1677-8>.
  42. Park SY, Kwon JS, Kim JY, Kim SM, Jang YR, Kim MC, et al. Severe fever with thrombocytopenia syndrome-associated encephalopathy/encephalitis. *Clin Microbiol Infect* 2018;24(4):432.e1 – 4. <http://dx.doi.org/10.1016/j.cmi.2017.09.002>.
  43. Yoshikawa T, Fukushi S, Tani H, Fukuma A, Taniguchi S, Toda S, et al. Sensitive and specific PCR systems for detection of both Chinese and Japanese severe fever with thrombocytopenia syndrome virus strains and prediction of patient survival based on viral load. *J Clin Microbiol* 2014;52(9):3325 – 33. <http://dx.doi.org/10.1128/JCM.00742-14>.
  44. Chen HB, Hu K, Zou JJ, Xiao JX. A cluster of cases of human-to-human transmission caused by severe fever with thrombocytopenia syndrome bunyavirus. *Int J Infect Dis* 2013;17(3):e206 – 8. <http://dx.doi.org/10.1016/j.ijid.2012.11.006>.
  45. Hu B, Cai K, Liu M, Li WJ, Xu JQ, Qiu F, et al. Laboratory detection and molecular phylogenetic analysis of severe fever with thrombocytopenia syndrome virus in Hubei Province, central China. *Arch Virol* 2018;163(12):3243 – 54. <http://dx.doi.org/10.1007/s00705-018-3993-5>.
  46. Jalal S, Hwang SY, Kim CM, Kim DM, Yun NR, Seo JW, et al. Comparison of RT-PCR, RT-nested PCRs, and real-time PCR for diagnosis of severe fever with thrombocytopenia syndrome: a prospective study. *Sci Rep* 2021;11(1):16764. <http://dx.doi.org/10.1038/s41598-021-96066-4>.
  47. Li ZF, Cui LB, Zhou MH, Qi X, Bao CJ, Hu JL, et al. Development and application of a one-step real-time RT-PCR using a minor-groove-binding probe for the detection of a novel bunyavirus in clinical specimens. *J Med Virol* 2013;85(2):370 – 7. <http://dx.doi.org/10.1002/jmv.23415>.
  48. Zhu YY, Wu HY, Gao J, Zhou X, Zhu RY, Zhang CZ, et al. Two confirmed cases of severe fever with thrombocytopenia syndrome with pneumonia: implication for a family cluster in East China. *BMC Infect Dis* 2017;17(1):537. <http://dx.doi.org/10.1186/s12879-017-2645-9>.
  49. Tian W, Ren XX, Gao X, Zhang YY, Chen ZH, Zhang W. Accuracy of reverse-transcription polymerase chain reaction and loop-mediated isothermal amplification in diagnosing severe fever with thrombocytopenia syndrome: A systematic review and meta-analysis. *J Med Virol* 2022;94(12):5922 – 32. <http://dx.doi.org/10.1002/jmv.28068>.
  50. Xu HH, Zhang L, Shen GQ, Feng C, Wang XY, Yan J, et al. Establishment of a novel one-step reverse transcription loop-mediated isothermal amplification assay for rapid identification of RNA from the severe fever with thrombocytopenia syndrome virus. *J Virol Methods* 2013;194(1 – 2):21 – 5. <http://dx.doi.org/10.1016/j.jviromet.2013.07.037>.
  51. Cui LB, Ge YY, Qi X, Xu GL, Li HJ, Zhao KC, et al. Detection of severe fever with thrombocytopenia syndrome virus by reverse transcription-cross-priming amplification coupled with vertical flow visualization. *J Clin Microbiol* 2012;50(12):3881 – 5. <http://dx.doi.org/10.1128/JCM.01931-12>.
  52. Huang MQ, Liu SH, Xu YN, Li AQ, Wu W, Liang MF, et al. CRISPR/Cas12a technology combined with RPA for rapid and portable SFTSV detection. *Front Microbiol* 2022;13:754995. <http://dx.doi.org/10.3389/fmicb.2022.754995>.
  53. Yun SM, Lee YJ, Choi W, Kim HC, Chong ST, Chang KS, et al. Molecular detection of severe fever with thrombocytopenia syndrome and tick borne encephalitis viruses in ixodid ticks collected from vegetation, Republic of Korea, 2014. *Ticks Tick Borne Dis* 2016;7(5):970 – 8. <http://dx.doi.org/10.1016/j.ttbdis.2016.05.003>.
  54. Park SW, Ryou J, Choi WY, Han MG, Lee WJ. Epidemiological and clinical features of severe fever with thrombocytopenia syndrome during an outbreak in South Korea, 2013-2015. *Am J Trop Med Hyg* 2016;95(6):1358 – 61. <http://dx.doi.org/10.4269/ajtmh.16-0251>.
  55. Yoshikawa T, Shimajima M, Fukushi S, Tani H, Fukuma A, Taniguchi S, et al. Phylogenetic and geographic relationships of severe fever with thrombocytopenia syndrome virus in China, South Korea, and Japan. *J Infect Dis* 2015;212(6):889 – 98. <http://dx.doi.org/10.1093/infdis/jiv144>.
  56. Zeng PB, Yang ZD, Bakkour S, Wang BJ, Qing S, Wang JX, et al. Development and validation of a real-time reverse transcriptase PCR assay for sensitive detection of SFTSV. *J Med Virol* 2017;89(7):1131 – 8. <http://dx.doi.org/10.1002/jmv.24760>.
  57. Ishijima K, Tatemoto K, Park E, Kimura M, Fujita O, Taira M, et al. Lethal disease in dogs naturally infected with severe fever with thrombocytopenia syndrome virus. *Viruses* 2022;14(9):1963. <http://dx.doi.org/10.3390/v14091963>.
  58. Kang JG, Oh SS, Jo YS, Chae JB, Cho YK, Chae JS. Molecular

- detection of severe fever with thrombocytopenia syndrome virus in Korean domesticated pigs. *Vector Borne Zoonotic Dis* 2018;18(8):450 – 2. <http://dx.doi.org/10.1089/vbz.2018.2310>.
59. Rim JM, Han SW, Cho YK, Kang JG, Choi KS, Jeong H, et al. Survey of severe fever with thrombocytopenia syndrome virus in wild boar in the Republic of Korea. *Ticks Tick Borne Dis* 2021;12(6):101813. <http://dx.doi.org/10.1016/j.ttbdis.2021.101813>.
  60. Gowen BB, Westover JB, Miao JX, Van Wettere AJ, Rigas JD, Hickerson BT, et al. Modeling severe fever with thrombocytopenia syndrome virus infection in golden Syrian hamsters: importance of STAT2 in preventing disease and effective treatment with favipiravir. *J Virol* 2017;91(3):e01942 – 16. <http://dx.doi.org/10.1128/JVI.01942-16>.
  61. Tani H, Fukuma A, Fukushi S, Taniguchi S, Yoshikawa T, Iwata-Yoshikawa N, et al. Efficacy of T-705 (Favipiravir) in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus. *mSphere* 2016;1(1):e00061 – 15. <http://dx.doi.org/10.1128/mSphere.00061-15>.
  62. Notomi T, Mori Y, Tomita N, Kanda H. Loop-mediated isothermal amplification (LAMP): principle, features, and future prospects. *J Microbiol* 2015;53(1):1 – 5. <http://dx.doi.org/10.1007/s12275-015-4656-9>.
  63. Soroka M, Wasowicz B, Rymaszewska A. Loop-mediated isothermal amplification (LAMP): the better sibling of PCR? *Cells* 2021;10(8):1931. <http://dx.doi.org/10.3390/cells10081931>.
  64. Yang GL, Li B, Liu LZ, Huang WC, Zhang W, Liu YD. Development and evaluation of a reverse transcription loop-mediated isothermal amplification assay for rapid detection of a new SFTS bunyavirus. *Arch Virol* 2012;157(9):1779 – 83. <http://dx.doi.org/10.1007/s00705-012-1348-1>.
  65. Huang XY, Hu XN, Ma H, Du YH, Ma HX, Kang K, et al. Detection of new bunyavirus RNA by reverse transcription-loop-mediated isothermal amplification. *J Clin Microbiol* 2014;52(2):531 – 5. <http://dx.doi.org/10.1128/JCM.01813-13>.
  66. Lee JW, Won YJ, Kang LH, Lee SG, Park SW, Paik SY. Development of a real-time loop-mediated isothermal amplification method for the detection of severe fever with thrombocytopenia syndrome virus. *J Microbiol* 2020;58(8):711 – 5. <http://dx.doi.org/10.1007/s12275-020-0109-1>.
  67. Sano S, Fukushi S, Yamada S, Harada S, Kinoshita H, Sugimoto S, et al. Development of an RT-LAMP assay for the rapid detection of SFTS virus. *Viruses* 2021;13(4):693. <http://dx.doi.org/10.3390/v13040693>.
  68. Ishijima K, Yokono K, Park E, Taira M, Tatamoto K, Kuroda Y, et al. Simple and rapid detection of severe fever with thrombocytopenia syndrome virus in cats by reverse transcription-loop-mediated isothermal amplification (RT-LAMP) assay using a dried reagent. *J Vet Med Sci* 2023;85(3):329 – 33. <http://dx.doi.org/10.1292/jvms.22-0523>.
  69. Li J, Macdonald J, Von Stetten F. Review: a comprehensive summary of a decade development of the recombinase polymerase amplification. *Analyst* 2019;144(1):31 – 67. <http://dx.doi.org/10.1039/c8an01621f>.
  70. Lobato IM, O'Sullivan CK. Recombinase polymerase amplification: basics, applications and recent advances. *Trends Analyt Chem* 2018;98:19 – 35. <http://dx.doi.org/10.1016/j.trac.2017.10.015>.
  71. Daher RK, Stewart G, Boissinot M, Bergeron MG. Recombinase polymerase amplification for diagnostic applications. *Clin Chem* 2016;62(7):947 – 58. <http://dx.doi.org/10.1373/clinchem.2015.245829>.
  72. James A, Macdonald J. Recombinase polymerase amplification: Emergence as a critical molecular technology for rapid, low-resource diagnostics. *Expert Rev Mol Diagn* 2015;15(11):1475 – 89. <http://dx.doi.org/10.1586/14737159.2015.1090877>.
  73. Tan MY, Liao C, Liang LN, Yi XL, Zhou ZH, Wei GJ. Recent advances in recombinase polymerase amplification: principle, advantages, disadvantages and applications. *Front Cell Infect Microbiol* 2022;12:1019071. <http://dx.doi.org/10.3389/fcimb.2022.1019071>.
  74. Park BJ, Yoo JR, Heo ST, Kim M, Lee KH, Song YJ. A CRISPR-Cas12a-based diagnostic method for Cas12a-based diagnostic method for multiple genotypes of severe fever with thrombocytopenia syndrome virus. *PLoS Negl Trop Dis* 2022;16(8):e0010666. <http://dx.doi.org/10.1371/journal.pntd.0010666>.
  75. Lee H, Kim EJ, Song JY, Choi JS, Lee JY, Cho IS, et al. Development and evaluation of a competitive enzyme-linked immunosorbent assay using a monoclonal antibody for diagnosis of severe fever with thrombocytopenia syndrome virus in bovine sera. *J Vet Sci* 2016;17(3):307 – 14. <http://dx.doi.org/10.4142/jvs.2016.17.3.307>.
  76. Liu Y, Li Q, Hu WF, Wu JB, Wang YB, Mei L, et al. Person-to-person transmission of severe fever with thrombocytopenia syndrome virus. *Vector Borne Zoonotic Dis* 2012;12(2):156 – 60. <http://dx.doi.org/10.1089/vbz.2011.0758>.
  77. Yu MA, Jeong HW, Park SJ, Kim YI, Kwon HI, Kim EH, et al. Evaluation of two different enzyme-linked immunosorbent assay for severe fever with thrombocytopenia syndrome virus diagnosis. *Clin Exp Vaccine Res* 2018;7(1):82 – 6. <http://dx.doi.org/10.7774/cevr.2018.7.1.82>.
  78. Tran XC, Kim SH, Lee JE, Kim SH, Kang SY, Binh ND, et al. Serological evidence of severe fever with thrombocytopenia syndrome virus and IgM positivity were identified in healthy residents in Vietnam. *Viruses* 2022;14(10):2280. <http://dx.doi.org/10.3390/v14102280>.
  79. Lundu T, Tsuda Y, Ito R, Shimizu K, Kobayashi S, Yoshii K, et al. Targeting of severe fever with thrombocytopenia syndrome virus structural proteins to the ERGIC (endoplasmic reticulum Golgi intermediate compartment) and Golgi complex. *Biomed Res* 2018;39(1):27 – 38. <http://dx.doi.org/10.2220/biomedres.39.27>.
  80. Yu FX, Du YH, Huang XY, Ma H, Xu BL, Adungo F, et al. Application of recombinant severe fever with thrombocytopenia syndrome virus nucleocapsid protein for the detection of SFTSV-specific human IgG and IgM antibodies by indirect ELISA. *Virol J* 2015;12:117. <http://dx.doi.org/10.1186/s12985-015-0350-0>.
  81. Duan YQ, Wu W, Zhao QZ, Liu SH, Liu HY, Huang MQ, et al. Enzyme-antibody-modified gold nanoparticle probes for the ultrasensitive detection of nucleocapsid protein in SFTSV. *Int J Environ Res Public Health* 2020;17(12):4427. <http://dx.doi.org/10.3390/ijerph17124427>.